Walleye Capital
NMRA icon

Walleye Capital’s Neumora Therapeutics NMRA Stock Holding History

Walleye Capital’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17K Buy
10,000
+1,500
+18% +$2.86K ﹤0.01% 4419
2026
Q1 		$16.6K Sell
8,500
-12,800
-60% -$33.2K ﹤0.01% 4098
2025
Q4 		$38.1K Buy
+21,300
New +$46.6K ﹤0.01% 4142

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Walleye Capital's NMRA Position: Q2 2026 in Review

Walleye Capital increased its Neumora Therapeutics (NMRA) stake by 40% in Q2 2026, buying an estimated $4.08K and bringing the position to 7,521 shares worth $12.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4464.

Walleye Capital first reported a position in NMRA in Q4 2025 and has held it in 3 quarters since. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Walleye Capital held 7,521 shares of Neumora Therapeutics worth $12.8K as of Q2 2026.
  • Walleye Capital bought 2,141 Neumora Therapeutics shares in Q2 2026, an estimated $4.08K.
  • Neumora Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #4464 holding.
  • Walleye Capital first reported a position in Neumora Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.